Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cephalon Licenses Acusphere Product

by Ann M. Thayer
November 3, 2008 | A version of this story appeared in Volume 86, Issue 44

Cephalon is paying $20 million in up-front financing to Acusphere for an exclusive worldwide license to AI-525, a preclinical-stage injectable form of the anti-inflammatory drug celecoxib, which is the active ingredient in Pfizer's Celebrex. The formulation uses Acusphere's drug delivery technology for hydrophobic drugs. The deal includes a $15 million milestone payment and royalties on sales if AI-525, which targets postoperative pain relief, is approved. Cephalon also has an option to license Acusphere's Imagify, a cardiovascular imaging agent based on perflubutane-containing polymer microspheres. If exercised, Cephalon would pay Acusphere $40 million upon FDA approval of Imagify, as well as royalties.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.